Award and Exercise of Nil Cost Options under VCP

RNS Number : 2999A
Assura PLC
25 September 2015
 

25 September 2015

 

Assura plc

 

Award and Exercise of Nil Cost Options under VCP

 

Assura plc ("Assura"), the leading primary care property investor and developer announces that, following the completion of the first measurement period of the Assura Group Value Creation Plan ("VCP") on 20 August 2015, Nil Cost Options were today awarded to persons discharging managerial responsibilities ("PDMRs") and staff over 24,999,950 shares in Assura calculated in accordance with the Rules of the VCP. On 25 September 2015, all PDMRs and staff exercised that element of their awards (50% by number) which is exercisable under the Rules of the VCP. The remaining nil cost options are exercisable subject to the achievement of performance hurdles in 2016 and 2017.

 

The table below shows the number of nil cost options awarded to PDMRs, the amount they have subsequently exercised and the amount of shares they will receive after deduction of income tax and national insurance liabilities.

 


Number of

Nil Cost Options awarded

Number of

Nil Cost Options exercised

Number of shares receivable after deduction of

Income Tax and National Insurance

Graham Roberts (Chief Executive)

11,779,255

5,889,628

3,121,503

Jonathan Murphy (Finance Director)

5,153,423

2,576,712

1,365,657

Andrew Darke

5,889,627

2,944,814

1,560,751

Paul Carroll

309,203

154,602

81,939

Spencer Kenyon

282,701

141,351

75,308

Carolyn Jones

229,693

114,847

62,799

 

On 25 September Andrew Darke, Paul Carroll, Spencer Kenyon and Carolyn Jones, being PDMRs (but not directors) in the Company, entered into irrevocable commitments to sell 750,000, 81,939, 75,308 and 62,799 shares respectively. The sales will take place over a number of days and the price achieved will be announced after the sales are completed.

 

The income tax and national insurance liabilities arising for individuals are recovered from the individuals through the cancellation of the relevant number of shares or through deduction from the proceeds of the share disposals. In the case of Graham Roberts and Jonathan Murphy, who are not making any disposals, the relevant market price for taxation purposes is 52.875 pence per share being the mid-market price at close of business on 24 September. For the remaining PDMRs the income tax and NI liabilities are dependent on the price achieved on the disposals.

 

As a result of the above, the increases in the shareholdings of the PDMRs are as follows:

 

Directors


Shareholding on

23 September 2015

Shareholding

 post exercise

Graham Roberts (Chief Executive)

3,100,000

6,221,503

Jonathan Murphy (Finance Director)

534,947

1,900,604

 

Other PDMRs


Shareholding on

23 September 2015

Shareholding

 post exercise and disposal

Andrew Darke

147,988

958,739

Paul Carroll

-

-

Spencer Kenyon

38,571

38,571

Carolyn Jones

-

-

Orla Ball

-

-

 

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

- Ends -

 

For more information, please contact:

 

Assura plc

 

Tel: 01925 420660

Orla Ball

Carolyn Jones


 

Finsbury

 

Tel: 0207 251 3801

Gordon Simpson

 

 

Notes to Editors

Assura is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington and listed on the London Stock Exchange, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 31 March 2015, Assura's property portfolio was valued at £931 million.

 

Further information is available at www.assuraplc.com .


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRPGUQCBUPAGQA

Companies

Assura (AGR)
UK 100